EGFR+ Lung Cancer

March 18th 2025

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

January 29th 2025

The phase 2b REZILIENT1 trial of zipalertinib in EGFR+ non–small cell lung cancer met its overall response rate primary end point with a consistent safety profile.

January 28th 2025

A pooled analysis of sunvozertinib in EGFR TKI-resistant NSCLC showed promising antitumor activity and favorable safety, achieving a 27.5% objective response rate.

January 20th 2025

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.